ReNeuron Group plc Block Listing Review and Total Voting Rights (5877K)

TIDMRENE

RNS Number : 5877K

ReNeuron Group plc

22 September 2016

 
 22 September 2016   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or "the Company")

Block Listing Review and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 
 Name:                                ReNeuron Group plc 
-----------------------------------  ----------------------- 
 Name of Scheme:                      ReNeuron Share Option 
                                       Schemes 
-----------------------------------  ----------------------- 
 Period of Return:                    From 29 September 2015 
                                       to 21 September 2016 
-----------------------------------  ----------------------- 
 Balance of unallotted                98,161,413 Ordinary 
  securities under scheme(s)           Shares (of 1p each) 
  from previous return: 
-----------------------------------  ----------------------- 
 Plus: The amount by                  N/A 
  which the block scheme(s) 
  has been increased 
  since the date of the 
  last Review (if any 
  increase has been applied 
  for): 
-----------------------------------  ----------------------- 
 Less: Number of securities 
  issued/allotted under                 7,878,902 Ordinary 
  scheme(s) during period               Shares 
-----------------------------------  ----------------------- 
 Equals: Balance under                90,282,511 Ordinary 
  scheme(s) not yet issued/allotted    Shares 
  at end of period: 
-----------------------------------  ----------------------- 
 Number and class of                  2,000,000 Ordinary 
  securities originally                Shares on 13 May 2010 
  admitted and the date 
  of admission: 
-----------------------------------  ----------------------- 
 
 
 

Total Voting Rights

The Company has 3,164,618,541 ordinary shares in issue, all with voting rights. The Company holds no ordinary shares in treasury. The figure of 3,164,618,541 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

ENDS

ENQUIRIES:

 
ReNeuron                                                            [phone] 
Olav Hellebø , Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                                            [phone] 
Mark Court, Sophie Cowles, Stephanie Watson 
 
Stifel Nicolaus Europe Limited                                      [phone] 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker) 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCAKBDPDBKDPCB

(END) Dow Jones Newswires

September 22, 2016 08:00 ET (12:00 GMT)